Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7532.084 | 0.9321 | 0.8271 | 0.7770 | |
| T47D | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7543.084 | 0.9960 | 0.9940 | 1.3431 | |
| SUM185PE | TNBC | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15332.203 | 0.0117 | -0.9962 | 0.7106 | |
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 66.7 | uM | 14607.189 | 0.0157 | -0.9029 | 1.3733 | |
| CAMA-1 | HR+ | Luminal | MG-132 | Proteasome | Proteasome | 66.7 | uM | 10755.145 | 0.0577 | -0.9511 | 0.7688 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11056.158 | 0.0039 | -0.7360 | 2.7355 | |
| HCC1419 | HER2amp | Luminal | FTase Inhibitor I | Ftase | MAPK | 66.7 | uM | 12001.167 | 0.8952 | 0.6221 | 0.5287 | |
| 600MPE | HR+ | Luminal | MG-132 | Proteasome | Proteasome | 66.7 | uM | 14197.189 | 0.3563 | -0.0639 | 1.3593 | |
| AU565 | HER2amp | Luminal | MG-132 | Proteasome | Proteasome | 66.7 | uM | 10880.145 | 0.0198 | -0.8600 | 1.4751 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7473.091 | 1.1810 | 1.1480 | 2.3297 | |
| MDA-MB-415 | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7512.084 | 1.0925 | 1.2499 | 0.7511 | |
| SUM52PE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11852.158 | 0.0107 | -0.9362 | 1.3172 | |
| MDA-MB-453 | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7517.084 | 0.8118 | 0.7247 | 1.4076 | |
| SUM185PE | TNBC | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15332.203 | 0.0117 | -0.9962 | 0.7106 | |
| MDA-MB-415 | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7510.084 | 0.9351 | 0.8517 | 0.8702 | |
| MDA-MB-361 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7507.084 | 0.5197 | 0.1154 | 1.1207 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7498.091 | 0.8376 | 0.7131 | 1.1445 | |
| MDA-MB-361 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7506.085 | 0.6492 | 0.3497 | 1.0985 | |
| MDA-MB-361 | HER2amp | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7508.084 | 0.4382 | -0.3097 | 0.7756 | |
| MDA-MB-415 | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7511.084 | 0.7213 | 0.5041 | 1.1467 | |
| MDA-MB-453 | TNBC | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7518.084 | 0.8321 | 0.7409 | 1.3244 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7474.09 | 1.1395 | 1.1099 | 2.4405 | |
| MDA-MB-175-VII | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7499.084 | 0.9204 | 0.8028 | 0.7991 | |
| 184A1 | NM | Basal | FTase Inhibitor I | Ftase | MAPK | 66.7 | uM | 12509.167 | 1.0388 | 1.0541 | 1.4256 | |
| MDA-MB-175-VII | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 66.7 | uM | 7500.084 | 1.0786 | 1.2780 | 0.5811 |